Introduction {#j_bjmg-2016-0007_s_001}
============

Infertility is a state of failure to conceive in a year of unprotected intercourse with the same partner \[[@j_bjmg-2016-0007_ref_001]\]. The male factors are responsible of infertility in 20.0 to 25.0% of couples \[[@j_bjmg-2016-0007_ref_002]\]. In men, the main causes of infertility are oligospermia, asthenospermia, teratozoospermia and azoospermia \[[@j_bjmg-2016-0007_ref_003],[@j_bjmg-2016-0007_ref_004]\]. Like other nutritional factors, availability of bioactive folate has recently been found to be related to male fertility \[[@j_bjmg-2016-0007_ref_005]\].

Folates are an inter-convertible group of enzymes that metabolize amino acid, synthesize and methylate deoxy-ribonuleotides (dNTPs) \[[@j_bjmg-2016-0007_ref_006],[@j_bjmg-2016-0007_ref_007]\]. Methyltetrahy-drofolate (MethylTHF) is the biologically active form of folate in plasma. An important enzyme, methylene-tetrahydrofolate reductase *(MTHFR)*, reduces 5,10 methylenetetrahydrofolate into 5, MethylTHF and during this reduction, a homocysteine is converted into methionine by attaining a methyl group from methylenetetrahydrofolate \[[@j_bjmg-2016-0007_ref_008]\].

Methionine is converted to S-adenosyl methionine that acts as a 'methyl' donor for DNA methylation. The 5,10 methylenetetrahydrofolate converts uracil into thymine for DNA synthesis \[[@j_bjmg-2016-0007_ref_009]\]. Therefore, deficiency in folate intake or polymorphism(s) in the enzymes of the folate pathway may result in aberrant DNA synthesis and methylation, especially in rapidly dividing cells such as bone marrow and spermatogonia \[[@j_bjmg-2016-0007_ref_010]\].

The *MTHFR* gene is composed of 11 exons and is located on the short arm of chromosome 1 at 1p36.22 \[[@j_bjmg-2016-0007_ref_008],[@j_bjmg-2016-0007_ref_011]\]. Being an important enzyme of folate metabolism, the *MTHFR* gene product has been studied and found in a total of 65 polymorphisms. The C677T (rs1801133) polymorphism in the *MTHFR* gene reduces the enzyme activity by 35.0% \[[@j_bjmg-2016-0007_ref_011]\] resulting in impairment of nucleic acid metabolic pathways. However, the condition can be managed by folic acid supplementation for determining the frequency of the *MTHFR* C677T mutation is a prerequisite.

The results of many of the molecular epidemiological studies on the association of the *MTHFR* C677T polymorphism and male infertility remain controversial due to small sample size, ambiguously defining infertility and confounding factors including ethnicity. In the present study, we determined an association between idiopathic sperm disorders and the *MTHFR* 677 CT polymorphism.

Materials and Methods {#j_bjmg-2016-0007_s_002}
=====================

Sample Population {#j_bjmg-2016-0007_s_002_s_001}
-----------------

Initially, 1234 men with primary infertility (the couples never conceived) were recruited from various diagnostic setups, hakeems (Muslim physicians) and private clinics in two cities of Rawalpindi and Islamabad, Pakistan, for a period of 2 years (2011 and 2012). A cohort of 348 proven fathers (had at least two children), residents of the same area, was also taken as a control group.

Inclusion and Exclusion Criteria {#j_bjmg-2016-0007_s_002_s_002}
--------------------------------

After approval and permission of the concerned authorities, infertile men fulfilling the World Health Organization (WHO) criteria of failure to conceive during 1 year of unprotected intercourse with the same partner were recruited \[[@j_bjmg-2016-0007_ref_001]\]. Only those men, whose partners were already screened and had normal reproductive functions, were included. The men with other physiological disorders, congenital and psychological disorders including diabetes, allergies, timing of the onset of puberty, cryptorchidism, testicular torsion, ectopic testis, single testis and testicular damage at birth and varicocele were excluded. The men with mental disorders, *i.e*., depression \[[@j_bjmg-2016-0007_ref_012]\], anxiety \[[@j_bjmg-2016-0007_ref_013]\] and stress \[[@j_bjmg-2016-0007_ref_014]\], screened by using standard scales, respectively, were also excluded. The past and present infections (mumps, high fever, tuberculosis, lung infections, reproductive tract infections and antisperm antibodies) and testicular or abdominal injury/surgery or vasectomy and Y-chromosome micro-deletions, were also excluded. Moreover, men (both fertile and infertile) with hormonal disorders \[tri-iodothyronine (T~3~), tetra-iodothyronine (T~4~), thyroid stimulating hormone (TSH), follicle stimulating hormone (FSH), luteinizing hormone (LH), testosterone (T) and prolactin\], and suspected lifestyle factors \[smoking \>5 cigarette (\~5 gm tobacco)/day; tea/coffee/soft drinks (one or all) \>3 times/ day or \>600 mL (three cups)/day; wearing tight clothes \>3 days a week and \>12 hours/day for at least 1 year\] were also excluded from the study.

Consequently, a total 437 idiopathic infertile men including 57 azoospermic, 66 oligospermic, 44 asthenozoospermic, 29 teratozoospermic, 20 oligoasthenospermic and 221 infertile normospermic men were recruited, after ruling out nongenetic factors. Moreover, 218 normospermic fertile men who had two children (or more), were included as controls. The samples and controls screened for *MTHFR* C677T belonged to the Punjabi ethnic group as self-defined by subjects.

Semen Sampling {#j_bjmg-2016-0007_s_002_s_003}
--------------

The semen samples were initially collected for analysis of a suspected fertility problem in men. The semen samples were also obtained from fertile men (control group). Each individual gave semen samples twice by masturbation after 3-5 days of abstinence, their written consent was obtained for the sample to be used further in molecular research.

Blood Sampling {#j_bjmg-2016-0007_s_002_s_004}
--------------

At least 10 mL of a single blood sample was collected from the antecubital vein of each subject and stored in vacutainers with EDTA as anticoagulant. Blood samples were immediately transported to the Genetics Laboratory, Institute of Biomedical Sciences and Genetic Engineering (IBGE), Islamabad, Pakistan, where the plasma was separated from all samples by cen-trifugation and stored at −25 °C until further analysis. The cellular portion was used for DNA extraction for genetic analysis.

Sample Analyses {#j_bjmg-2016-0007_s_003}
===============

Semen Analysis {#j_bjmg-2016-0007_s_003_s_001}
--------------

Semen parameters (semen volume, sperm concentration, sperm motility, sperm morphology, liquefaction time, pH and colour) were determined in a private laboratory by an expert using standard methods. The semen samples were categorized into one of the semen group defined by WHO \[[@j_bjmg-2016-0007_ref_001]\]. (Table 3.1). The volume was measured using a graduated glass pipette. The sperm concentration was counted using a sperm counting chamber (Jiansu Sanwe Medical Science and Technology Co. Ltd., Xuzhou, China). The concentration, motility and morphology of sperm cells were observed using a binocular microscope at x100 magnification (Olympus Optical Co. Ltd., Tokyo, Japan). The semen pH was determined with a digital pH meter.

Genetic Analysis {#j_bjmg-2016-0007_s_003_s_002}
----------------

Total genomic DNA was extracted from blood samples using a standard phenol/ chloroform extraction method.

*MTHFR* C677T Genotyping {#j_bjmg-2016-0007_s_003_s_003}
------------------------

The *MTHFR* C677T polymorphism was analyzed by polymerase chain reaction (PCR) of the genomic DNA with primers 5'-ACC CAC AGA AAA TAC CCA G-3' (forward) and 5'-TGC CCC ATT ATT TA-3' (reverse) (Alpha DNA, Montreal, Quebec, Canada) with an initial step consisting of denaturation for 4 min. at 94 °C, annealing for 45 seconds at 60 °C, extension for 45 seconds at 72 °C, followed by 35 cycles of denaturation at 94 °C for 45 seconds, annealing at 60 °C for 45 seconds, extension at 72 °C for 45 seconds, and a final extension at 72 °C for 10 min. The amplified PCR products were digested with *HinfI* restriction endonuclease (Fermentas Life Sciences, Burlington, ON, Canada) as the C677T polymorphism creates a restriction site for it.

Gel Electrophoresis {#j_bjmg-2016-0007_s_003_s_004}
-------------------

The digested product was elec-trophoresed on a 3.0% agarose gel with ethidium bromide staining which was then visualized through ultraviolet transillumination. The normal allele with cytosine at position 677 (C677) formed an undigested fragment of 198 bp, while the mutant allele with thymine in position 677 (T677) formed fragments of 175 and 23 bp.

Statistical Analysis {#j_bjmg-2016-0007_s_003_s_005}
--------------------

The allele frequency of the *MTHFR* 677C\>T polymorphism was determined by counting alleles through electrophoresis gel analysis. The χ^2^ analysis was used to determine the Hardy-Weinberg equilibrium of the alleles in the population.

![DNA electrophoresis of the *MTHFR* C677T mutation on 3.0% agarose gel. 1: undigested; homozygous normal allele (CC) 198 bp; 2 and 3: heterozygous allele (CT) 175 and 23 bp.](j_bjmg-2016-0007_fig_001){#j_bjmg-2016-0007_fig_001}

The association of the *MTHFR* 677C\>T polymorphism with subgroups of male infertility was determined by logistic regression analysis adjusting the effects of age, body mass index (BMI), occupation, working hours, and working shift. A *p* value of \<0.05 was considered statistically significant. All statistical analyses were performed using the International Business Machines (IBM) Statistical Package for the Social Sciences (SPSS) v20.0 for Windows (IBM SPSS; <http://www.ibm.com>).

Results {#j_bjmg-2016-0007_s_004}
=======

Genotype distribution of the *MTHFR* 677C\>T polymorphism of the 655 subjects analyzed: 472 (72.06%) subjects were homozygous for the C allele (CC), 166 (25.34%) subjects were heterozygous (CT), and 17 (2.60%) subjects were homozygous for the T allele (TT). The minor allele (T) frequency of the *MTHFR* 677C\>T polymorphism was 0.153, and the genotype distributions did not deviate from the Hardy-Weinberg equilibrium (p \>0.05) ([Tables 1](#j_bjmg-2016-0007_tab_001){ref-type="table"} and [2](#j_bjmg-2016-0007_tab_002){ref-type="table"}).

###### 

Allele frequencies of the *MTHFR* C677T mutation in the studied subjects.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient Group              Allele   Infertile Men *n* (%)   Fertile Men *n* (%)   OR (95% CI)         *p* Value   AOR (95% CI)       *p* Value
  -------------------------- -------- ----------------------- --------------------- ------------------- ----------- ------------------ ---------------------------------------------------------
  Azoospermic                C\       90 (78.95)\             404 (92.66)\          1\                  0.000       1\                 0.017[a](#j_bjmg-2016-0007_fn_001){ref-type="table-fn"}
                             T        24 (21.05)              32 (7.34)             3.37 (1.89-5.99)                2.05 (1.14-3.70)   

  Oligospermic               C\       95 (71.97)\             404 (92.66)\          1\                  0.000       1\                 0.000[a](#j_bjmg-2016-0007_fn_001){ref-type="table-fn"}
                             T        37 (28.03)              32 (7.34)             4.92 (2.91-8.30)                4.36 (2.52-7.53)   

  Asthenozoospermic          C\       64 (72.73)\             404 (92.66)\          1\                  0.000       1\                 0.001[a](#j_bjmg-2016-0007_fn_001){ref-type="table-fn"}
                             T        24 (27.27)              32 (7.34)             3.70 (2.09-6.52)                3.70 (1.98-6.89)   

  Teratozoospermic           C\       41 (70.69)\             404 (92.66)\          1\                  0.000       1\                 0.000[a](#j_bjmg-2016-0007_fn_001){ref-type="table-fn"}
                             T        17 (29.31)              32 (7.34)             5.23 (2.68-10.23)               3.31 (1.61-6.82)   

  OAT                        C\       29 (72.50)\             404 (92.66)\          1\                  0.021       1\                 0.008[a](#j_bjmg-2016-0007_fn_001){ref-type="table-fn"}
                             T        11 (27.50)              32 (7.34)             2.39 (1.14-5.03)                3.33 (1.37-8.07)   

  Infertile normospermic     C\       387 (87.56)\            404 (92.66)\          1\                  0.581       1\                 0.018[a](#j_bjmg-2016-0007_fn_001){ref-type="table-fn"}
                             T        55 (12.44)              32 (7.34)             0.90 (0.61-1.32)                1.77 (1.10-2.85)   

  Total infertile subjects   C\       706 (80.78)\            404 (92.66)\          1\                  0.012       1\                 0.016[a](#j_bjmg-2016-0007_fn_001){ref-type="table-fn"}
                             T        168 (19.22)             32 (7.34)             1.50 (1.10-2.05)                2.12 (1.38-3.92)   
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

A *p* value of \<0.05 was considered to be significant.

OR: odds ratio; 95% CI: 95% confidence interval; AOR: odds ratio adjusted for age, body mass index (BMI), occupation, working shift and hours; C: wild type; T: mutated; OAT: oligoasthenoteratospermic.

###### 

Genotype frequencies of the *MTHFR* C677T mutation in the studied subjects.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient Group              Genotype   Infertile Men *n* (%)   Fertile Men *n* (%)   OR (95% CI)            *p* Value   AOR (95% CI)          *p* Value
  -------------------------- ---------- ----------------------- --------------------- ---------------------- ----------- --------------------- ----------------------------------------------------------
  Azoospermic                CC\        36 (63.16)\             187 (85.78)\          1\                     \           1\                    \
                             CT\        18 (31.58)\             30 (13.76)\           3.12 (1.57-6.186)\     0.001\      2.59 (1.27-5.30)\     0.009[a](#j_bjmg-2016-0007_fn_008){ref-type="table-fn"}\
                             TT\        3 (5.26)\               1 (0.46)\             15.58 (1.58-154.06)\   0.019\      13.30 (1.23-33.20)\   0.033[a](#j_bjmg-2016-0007_fn_008){ref-type="table-fn"}\
                             CT + TT    21 (36.84)              31 (14.22)            3.52 (1.82-6.80)       0.000       2.12 (1.09-4.15)      0.027[a](#j_bjmg-2016-0007_fn_008){ref-type="table-fn"}

  Oligospermic               CC\        34 (51.52)\             187 (85.78)\          1\                     \           1\                    \
                             CT\        27 (40.91)\             30 (13.76)\           4.95 (2.62-9.35)\      0.000\      4.33 (2.18-8.59)\     0.000[a](#j_bjmg-2016-0007_fn_008){ref-type="table-fn"}\
                             TT\        5 (7.58)\               1 (0.46)\             27.50 (3.12-242-77)\   0.003\      24.05 (2.54-87.34)\   0.006[a](#j_bjmg-2016-0007_fn_008){ref-type="table-fn"}\
                             CT + TT\   32 (48.48)              31 (14.22)            5.58 (3.07-10.49)      0.000       5.01 (2.58-9.71)      0.000[a](#j_bjmg-2016-0007_fn_008){ref-type="table-fn"}

  Asthenozoospermic          CC\        22 (50.00)\             187 (85.78)\          1\                     \           1\                    \
                             CT\        20 (45.45)\             30 (13.76)\           5.67 (2.76-11.62)\     0.000\      5.10 (2.32-11.23)\    0.000[a](#j_bjmg-2016-0007_fn_008){ref-type="table-fn"}\
                             TT\        2 (4.55)\               1 (0.46)\             17.00 (1.48-195.20)\   0.023\      15.93 (1.22-97.81)\   0.035[a](#j_bjmg-2016-0007_fn_008){ref-type="table-fn"}\
                             CT + TT    22 (50.00)              31 (14.22)            6.03 (2.99-12.18)      0.000       5.03 (2.35-10.75)     0.000[a](#j_bjmg-2016-0007_fn_008){ref-type="table-fn"}

  Teratozoospermic           CC\        15 (51.72)\             187 (85.78)\          1\                     \           1\                    \
                             CT\        11 (37.39)\             30 (13.76)\           4.57 (1.92-10.89)\     0.000\      2.90 (1.09-7.76)\     0.033[a](#j_bjmg-2016-0007_fn_008){ref-type="table-fn"}\
                             TT\        3 (10.34)\              1 (0.46)\             37.40 (3.66-381-91)\   0.002\      30.99 (2.91-82.3)\    0.004[a](#j_bjmg-2016-0007_fn_008){ref-type="table-fn"}\
                             CT + TT    14 (48.28)              31 (14.22)            5.63 (2.48-12.80)      0.000       3.17 (1.27-7.91)      0.014[a](#j_bjmg-2016-0007_fn_008){ref-type="table-fn"}

  OAT                        CC\        10 (50.00)\             187 (85.78)\          1\                     \           1\                    \
                             CT\        9 (45.00)\              30 (13.76)\           5.61 (2.12-14.94)\     0.000\      4.10 (0.23-13.19)\    0.018[a](#j_bjmg-2016-0007_fn_008){ref-type="table-fn"}\
                             TT\        1 (5.00)\               1 (0.46)\             18.70 (1.09-321.32)\   0.044\      14.68 (0.61-68.20)\   0.098\
                             CT + TT    10 (50.00)              31 (14.22)            6.03 (2.32-15.68)      0.000       4.55 (1.46-14.14)     0.009[a](#j_bjmg-2016-0007_fn_008){ref-type="table-fn"}

  Infertile normospermic     CC\        168 (76.02)\            187 (85.78)\          1\                     \           1\                    \
                             CT\        51 (23.08)\             30 (13.76)\           1.89 (1.15-3.12)\      0.012\      1.92 (1.12-3.27)\     0.017[a](#j_bjmg-2016-0007_fn_008){ref-type="table-fn"}\
                             TT\        2 (0.90)\               1 (0.46)\             2.23 (0.20-24.77)\     0.515\      2.48 (0.22-28.28)\    0.464\
                             CT + TT    53 (23.98)              31 (14.22)            1.90 (1.17-3.12)       0.010       1.95 (1.17-3.26)      0.011[a](#j_bjmg-2016-0007_fn_008){ref-type="table-fn"}

  Total infertile subjects   CC\        285 (65.22)\            187 (85.78)\          1\                     \           1\                    \
                             CT\        136 (31.12)\            30 (13.76)\           2.97 (1.92-4.60)\      0.000\      1.81 (1.17-2.80)\     0.008[a](#j_bjmg-2016-0007_fn_008){ref-type="table-fn"}\
                             TT\        16 (3.66)\              1 (0.46)\             10.50 (1.38-79.83)\    0.023\      9.24 (1.20-70.92)\    0.032[a](#j_bjmg-2016-0007_fn_008){ref-type="table-fn"}\
                             CT + TT    152 (34.78)             31 (14.22)            3.22 (2.10-4.94)       0.000       2.01 (1.31-3.08)      0.001[a](#j_bjmg-2016-0007_fn_008){ref-type="table-fn"}
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

A *p* value of \<0.05 was considered to be significant.

OR: odds ratio; 95% CI: 95% confidence interval; AOR: odds ratio adjusted for age, body mass index (BMI), occupation, working shift and hours; C: wild type; T: mutated; OAT: oligoasthenoteratospermic.

Prevalence and Odds Ratios of Male Infertility According to Carriers of the Minor Allele of the *MTHFR* C677T Polymorphism. a) Allele frequencies {#j_bjmg-2016-0007_s_004_s_001}
-------------------------------------------------------------------------------------------------------------------------------------------------

The relative *MTHFR* 677 allele and genotype frequencies of the individual risk factors of the male infertility in the total populations are summarized in [Tables 1](#j_bjmg-2016-0007_tab_001){ref-type="table"} and [2](#j_bjmg-2016-0007_tab_002){ref-type="table"}. Results show that the *MTHFR* C\>T polymorphism increases the odds ratio (OR) \[2.12, 95% confidence interval (95% CI): 1.38-3.92\] of male infertility significantly *(p* \<0.05).

In addition, after classifying the men into different infertility groups, allelic frequencies were significantly different between infertile and fertile men. The minor allele (T) frequency was highest in teratospermic men (0.293%), followed by oligospermic (0.280%), oligoasthenoteratospermic (OAT) (0.275%), asthenospermic (0.273%), azoospermia (0.210%), normospermic infertile (0.124%) and fertile men (0.073%) ([Table 1](#j_bjmg-2016-0007_tab_001){ref-type="table"}).

Genotype Frequencies {#j_bjmg-2016-0007_s_004_s_002}
--------------------

According to [Table 2](#j_bjmg-2016-0007_tab_002){ref-type="table"}, men with *MTHFR* 677 CT and TT genotypes are at a greater risk (OR: 1.81, 95 %CI: 1.17-2.80, *p* = 0.008 and OR: 9.24, 95% CI: 1.20-70.92, *p* = 0.032, respectively) of male infertility. All the subgroups of male infertility (azoospermic, oligospermic, asthenospermic, OAT and normospermic infertile) had significantly *(p* \<0.05) higher frequencies of CT and TT genotype as compared to fertile men. The combined genotypes (CT + TT) were also found to be significantly associated with male infertility (OR: 2.01, 95 %CI: 1.31-3.08, *p* \<0.001) ([Table 2](#j_bjmg-2016-0007_tab_002){ref-type="table"}).

Discussion {#j_bjmg-2016-0007_s_005}
==========

Spermatogenesis is a complex process involving about 2000 genes and various non genetic factors. The gene mutations and disrupted expression may distort maturation of spermatocytes. DNA methylation ensures the regulated expression of genes. However, DNA methylation is done only in the presence of methionine. A homocysteine is converted into methionine by *MTHFR* through transferring a methyl group from methylenetetrahyfrofolate \[[@j_bjmg-2016-0007_ref_008]\]. Therefore, a mutation in the *MTHFR* such as C677T may reduce methylation of DNA \[[@j_bjmg-2016-0007_ref_011]\]. In addition, a reduced conversion of homocysteine into methionine may lead to hyper-homocysteinemia, and cause DNA and cell membrane damages, testicular arterial sclerosis, and impairment of spermatogenesis \[[@j_bjmg-2016-0007_ref_011],[@j_bjmg-2016-0007_ref_015]-[@j_bjmg-2016-0007_ref_017]\].

However, results of most of the molecular epidemiological studies on association of *MTHFR* 677CT polymorphism and male infertility remain controversial. A total of 20 of 41 studies showed association of the polymorphism with male infertility. Out of four \[[@j_bjmg-2016-0007_ref_018]-[@j_bjmg-2016-0007_ref_021]\] studies carried out on African populations, only one (\[[@j_bjmg-2016-0007_ref_018]\] showed a significant association of the 677T with infertility in Egyptian men. Furthermore, a study on Moroccan infertile men showed a protective role of the *MTHFR* 677T polymorphism \[[@j_bjmg-2016-0007_ref_022]\]. Comparatively, more than half the number of Asian studies (14 out of 22) \[[@j_bjmg-2016-0007_ref_022]-[@j_bjmg-2016-0007_ref_032],[@j_bjmg-2016-0007_ref_036]-[@j_bjmg-2016-0007_ref_038],[@j_bjmg-2016-0007_ref_041]-[@j_bjmg-2016-0007_ref_042]\] expressed this association, while only a few Caucasian studies (six out of 15) \[[@j_bjmg-2016-0007_ref_044]-[@j_bjmg-2016-0007_ref_047],[@j_bjmg-2016-0007_ref_050]-[@j_bjmg-2016-0007_ref_051]\] exhibited it.

Similarly, all the studies \[[@j_bjmg-2016-0007_ref_022]-[@j_bjmg-2016-0007_ref_028]\] except one \[[@j_bjmg-2016-0007_ref_029]\] reported a significant association of the 677T anomaly with male infertility. Seven studies on Indian populations reported contrasting observations to each other \[[@j_bjmg-2016-0007_ref_030]-[@j_bjmg-2016-0007_ref_036]\]. Four Indian studies \[[@j_bjmg-2016-0007_ref_030]-[@j_bjmg-2016-0007_ref_033]\] showed a significant association of mutant genotypes with infertility, while three studies \[[@j_bjmg-2016-0007_ref_034]-[@j_bjmg-2016-0007_ref_036]\] showed no statistically significant difference of 677 C\>T variants between infertile and fertile males. Dhillon *et al*. \[[@j_bjmg-2016-0007_ref_035]\] explained the variations in results that their study included a majority of OAT patients in comparison to the majority of azoospermic cases in the study by Singh *et al*. \[[@j_bjmg-2016-0007_ref_029]\]. Gupta *et al*. \[[@j_bjmg-2016-0007_ref_030]\] included both azoospermic and OAT individuals, showing a significant association of mutant alleles and genotypes with infertility. It was reported that the three Indian populations studied were not ethnically different \[[@j_bjmg-2016-0007_ref_030]\]. Three \[[@j_bjmg-2016-0007_ref_036]-[@j_bjmg-2016-0007_ref_038]\] of five \[[@j_bjmg-2016-0007_ref_036]-[@j_bjmg-2016-0007_ref_040]\] other Asian studies showed significantly higher mutant genotypes in infertile groups than fertile groups of Iranian men. Similarly, studies carried out on Korean infertile men also had contrasting results \[[@j_bjmg-2016-0007_ref_041]-[@j_bjmg-2016-0007_ref_043]\].

Moreover, in Caucasian populations, few studies reported that the polymorphism in *MTHFR* was a risk of male infertility \[[@j_bjmg-2016-0007_ref_044]-[@j_bjmg-2016-0007_ref_048]\]. However, other studies inferred that the mutant genotype is not such a risk \[[@j_bjmg-2016-0007_ref_049]-[@j_bjmg-2016-0007_ref_058]\]. Moreover, few studies gave contrasting conclusions for the same population \[[@j_bjmg-2016-0007_ref_047],[@j_bjmg-2016-0007_ref_048]\].

Therefore, the differences in the results could be attributed to other factors such as variations in recruitment of subjects, sample size, ethnicity and geographic factors ([Tables 3](#j_bjmg-2016-0007_tab_003){ref-type="table"} and [4](#j_bjmg-2016-0007_tab_004){ref-type="table"}). The results are also dependent on the reproductive health (testicular, hormonal, and epididymal, *etc*.), general health (infections, surgeries, fever and antibodies, *etc.)* and lifestyle factors (clothing, occupation, smoking, caffeine intake, etc.), which were not addressed while selecting subjects in many of the previous studies. There were eight studies \[[@j_bjmg-2016-0007_ref_018],[@j_bjmg-2016-0007_ref_022],[@j_bjmg-2016-0007_ref_023],[@j_bjmg-2016-0007_ref_026],[@j_bjmg-2016-0007_ref_027],[@j_bjmg-2016-0007_ref_031],[@j_bjmg-2016-0007_ref_037],[@j_bjmg-2016-0007_ref_049]\] that showed association of 677T with male infertility and seven studies \[[@j_bjmg-2016-0007_ref_020],[@j_bjmg-2016-0007_ref_039],[@j_bjmg-2016-0007_ref_040],[@j_bjmg-2016-0007_ref_050]-[@j_bjmg-2016-0007_ref_052],[@j_bjmg-2016-0007_ref_058]\] that lack association and did not mention criteria of selection of infertile men. Furthermore, nine studies \[[@j_bjmg-2016-0007_ref_023],[@j_bjmg-2016-0007_ref_024],[@j_bjmg-2016-0007_ref_026]-[@j_bjmg-2016-0007_ref_028],[@j_bjmg-2016-0007_ref_032],[@j_bjmg-2016-0007_ref_037],[@j_bjmg-2016-0007_ref_038],[@j_bjmg-2016-0007_ref_047]\] showing association and eight studies \[[@j_bjmg-2016-0007_ref_019],[@j_bjmg-2016-0007_ref_028],[@j_bjmg-2016-0007_ref_034],[@j_bjmg-2016-0007_ref_039],[@j_bjmg-2016-0007_ref_040],[@j_bjmg-2016-0007_ref_048],[@j_bjmg-2016-0007_ref_050],[@j_bjmg-2016-0007_ref_057]\] that showed no association, did not mention selection criteria of fertile men as a control group (data not shown).

###### 

Allelic distribution of the *MTHFR* C677T mutation in infertile patients and controls from various other populations.

  Study                             Country           Patients   Controls   Patients   Controls      OR    SE            Lower Limit   Upper Limit   *p* Value           
  --------------------------------- ----------------- ---------- ---------- ---------- ------------- ----- ------------- ------------- ------------- ----------- ------- -----------------------------------------------------------------------------------------------------------
  **African**                                                                                                                                                            
  \[[@j_bjmg-2016-0007_ref_018]\]   Egypt             139        90         133        125 (48.45)   126   54 (30.00)    2.19          0.20          1.47        3.28    0.000[a](#j_bjmg-2016-0007_fn_010){ref-type="table-fn"}[a](#j_bjmg-2016-0007_fn_010){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_019]\]   Egypt             107        107        163        51 (23.83)    156   58 (27.10)    0.84          0.22          0.54        1.30    0.438
  \[[@j_bjmg-2016-0007_ref_020]\]   Algeria           74         84         95         55 (36.67)    110   58 (35.52)    1.10          0.23          0.69        1.74    0.690
  \[[@j_bjmg-2016-0007_ref_021]\]   Morocco           344        690        523        165 (23.98)   988   392 (28.41)   0.80          0.11          0.64        0.98    0.033
  **Asian**                                                                                                                                                              
  \[[@j_bjmg-2016-0007_ref_022]\]   China             182        53         140        224 (61.54)   58    48 (45.28)    1.93          0.22          1.25        2.99    0.003[a](#j_bjmg-2016-0007_fn_010){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_023]\]   China             355        252        420        290 (40.85)   351   153 (30.36)   1.58          0.12          1.24        2.02    0.000[a](#j_bjmg-2016-0007_fn_010){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_024]\]   China             75         72         92         58 (38.67)    108   36 (25.00)    1.89          0.26          1.15        3.12    0.013[a](#j_bjmg-2016-0007_fn_010){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_025]\]   China             82         133        64         100 (60.98)   133   133 (50.00)   1.56          0.20          1.05        2.32    0.027[a](#j_bjmg-2016-0007_fn_010){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_026]\]   China             131        293        125        139 (52.65)   338   248 (42.32)   1.52          0.15          1.13        2.03    0.005[a](#j_bjmg-2016-0007_fn_010){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_027]\]   China             290        90         216        364 (62.76)   95    85 (47.22)    1.88          0.17          1.34        2.64    0.000[a](#j_bjmg-2016-0007_fn_010){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_028]\]   China             271        180        262        280 (51.66)   149   211 (58.61)   0.75          0.14          0.58        0.99    0.040[a](#j_bjmg-2016-0007_fn_010){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_029]\]   India             151        200        250        52 (17.22)    363   37 (9.25)     2.04          0.23          1.30        3.20    0.002[a](#j_bjmg-2016-0007_fn_010){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_030]\]   India             522        315        872        172 (16.48)   560   70 (11.11)    1.58          0.15          1.17        2.12    0.003[a](#j_bjmg-2016-0007_fn_010){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_031]\]   India             12         20         13         11 (45.83)    37    3 (7.50)      10.44         0.73          2.51        43.37   0.001[a](#j_bjmg-2016-0007_fn_010){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_032]\]   India             637        364        1048       226 (17.74)   627   99 (13.64)    1.37          0.13          1.06        1.76    0.017[a](#j_bjmg-2016-0007_fn_010){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_033]\]   India             206        230        358        54 (13.11)    418   42 (9.13)     1.50          0.22          0.98        2.30    0.062
  \[[@j_bjmg-2016-0007_ref_034]\]   India             179        200        239        119 (33.24)   240   160 (40.00)   0.75          0.15          0.55        1.01    0.054
  \[[@j_bjmg-2016-0007_ref_035]\]   India             100        100        186        14 (7.00)     181   19 (9.50)     0.72          0.37          0.35        1.47    0.365
  \[[@j_bjmg-2016-0007_ref_036]\]   Iran              164        328        196        132 (40.24)   436   220 (33.54)   1.33          0.14          1.01        1.67    0.039[a](#j_bjmg-2016-0007_fn_010){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_037]\]   Iran              118        132        161        75 (31.78)    206   58 (21.97)    1.65          0.20          1.11        2.47    0.014[a](#j_bjmg-2016-0007_fn_010){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_038]\]   Iran              242        255        327        157 (32.44)   386   124 (24.31)   1.49          0.14          1.13        1.97    0.005[a](#j_bjmg-2016-0007_fn_010){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_039]\]   Iran              266        77         402        130 (24.44)   74    80 (51.95)    0.30          0.19          0.21        0.43    0.100
  \[[@j_bjmg-2016-0007_ref_040]\]   Iran              300        303        430        170 (28.33)   426   180 (29.70)   0.94          0.13          0.73        1.20    0.600
  \[[@j_bjmg-2016-0007_ref_041]\]   Korea             371        396        410        332 (44.73)   490   302 (38.13)   1.31          0.10          1.07        1.61    0.009[a](#j_bjmg-2016-0007_fn_010){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_042]\]   Korea             360        325        411        309 (42.92)   402   248 (38.15)   1.22          0.11          0.98        1.51    0.073
  \[[@j_bjmg-2016-0007_ref_043]\]   Korea             85         246        104        66 (38.82)    280   212 (43.09    0.84          0.18          0.59        1.20    0.332
  **Caucasian**                                                                                                                                                          
  \[[@j_bjmg-2016-0007_ref_044]\]   Brazil            156        233        222        90 (28.85)    387   79 (16.95)    1.99          0.18          1.41        2.80    0.000[a](#j_bjmg-2016-0007_fn_010){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_045]\]   Brazil            133        173        183        83 (68.80)    299   47 (13.85)    2.89          0.21          1.93        4.31    0.000[a](#j_bjmg-2016-0007_fn_010){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_046]\]   Slovenia          100        111        109        91 (45.50)    144   78 (35.14)    1.54          0.20          1.04        2.28    0.030[a](#j_bjmg-2016-0007_fn_010){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_047]\]   Italy             59         46         54         64 (54.24)    57    35 (38.04)    1.93          0.28          1.11        3.36    0.020[a](#j_bjmg-2016-0007_fn_010){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_048]\]   Italy             93         105        111        75 (40.32)    119   91 (43.33)    0.88          0.20          0.59        1.32    0.545
  \[[@j_bjmg-2016-0007_ref_049]\]   Turkey            100        50         132        68 (34.00)    80    20 (20.00)    2.06          0.29          1.16        3.65    0.013[a](#j_bjmg-2016-0007_fn_010){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_050]\]   Germany           255        200        321        189 (37.09)   273   127 (31.75)   1.27          0.14          0.96        1.67    0.095
  \[[@j_bjmg-2016-0007_ref_051]\]   The Netherlands   77         113        112        42 (27.27)    148   78 (34.51)    0.71          0.23          0.45        1.11    0.137
  \[[@j_bjmg-2016-0007_ref_052]\]   Serbia            52         56         68         36 (34.62)    72    40 (35.71)    0.95          0.29          0.54        1.67    0.866
  \[[@j_bjmg-2016-0007_ref_053]\]   Poland            284        352        399        169 (29.75)   482   222 (31.53)   0.92          0.12          0.72        1.17    0.494
  \[[@j_bjmg-2016-0007_ref_054]\]   Jordan            150        150        197        103 (34.33)   215   85 (28.33)    1.32          0.18          0.97        1.87    0.114
  \[[@j_bjmg-2016-0007_ref_055]\]   Sweden            149        182        209        89 (29.87)    261   103 (28.30)   1.08          0.17          0.77        1.51    0.658
  \[[@j_bjmg-2016-0007_ref_056]\]   France            250        114        337        163 (32.00)   150   78 (34.21)    0.93          0.17          0.67        1.30    0.668
  \[[@j_bjmg-2016-0007_ref_057]\]   Russia            180        301        250        110 (30.56)   421   181 (30.07)   1.02          0.14          0.77        1.36    0.873
  \[[@j_bjmg-2016-0007_ref_058]\]   Canada            39         19         58         20 (51.22)    21    17 (44.74)    0.43          0.42          0.19        0.96    0.041[a](#j_bjmg-2016-0007_fn_010){ref-type="table-fn"}

A *p* value of \<0.05 was considered to be significant.

OR: odds ratio; SE: standard error.

###### 

Genetic distribution of the *MTHFR* C677T mutation in infertile patients and controls from various other populations.

  Study                             Country           Patients   Controls   Patients   Controls      OR    SE            Lower Limit   Upper Limit   *P* Value           
  --------------------------------- ----------------- ---------- ---------- ---------- ------------- ----- ------------- ------------- ------------- ----------- ------- ---------------------------------------------------------
  **African**                                                                                                                                                            
  \[[@j_bjmg-2016-0007_ref_018]\]   Egypt             139        90         109        133 (54.96)   144   111 (43.53)   1.58          0.18          1.11        2.26    0.011[a](#j_bjmg-2016-0007_fn_020){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_019]\]   Egypt             107        107        55         84 (60.43)    41    49 (54.44)    1.28          0.27          0.75        2.18    0.370
  \[[@j_bjmg-2016-0007_ref_020]\]   Algeria           74         84         31         43 (58.11)    36    48 (57.14)    1.04          0.32          0.55        1.96    0.902
  \[[@j_bjmg-2016-0007_ref_021]\]   Morocco           344        690        199        145 (42.15)   351   339 (49.13)   0.75          0.13          0.58        0.98    0.034[a](#j_bjmg-2016-0007_fn_020){ref-type="table-fn"}
  **Asian**                                                                                                                                                              
  \[[@j_bjmg-2016-0007_ref_022]\]   China             182        53         27         155 (85.16)   15    38 (71.70)    2.27          0.37          1.10        4.67    0.027[a](#j_bjmg-2016-0007_fn_020){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_023]\]   China             355        252        130        225 (63.38)   128   124 (49.21)   1.79          0.17          1.29        2.48    0.001[a](#j_bjmg-2016-0007_fn_020){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_024]\]   China             75         72         27         48 (64.00)    40    32 (44.44)    2.22          0.34          1.15        4.31    0.018[a](#j_bjmg-2016-0007_fn_020){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_025]\]   China             82         133        14         68 (82.93)    36    97 (72.93)    1.80          0.35          0.90        3.60    0.095
  \[[@j_bjmg-2016-0007_ref_026]\]   China             131        293        35         97 (73.48)    98    293 (74.94)   0.93          0.23          0.59        1.45    0.741
  \[[@j_bjmg-2016-0007_ref_027]\]   China             290        90         39         251 (86.55)   24    66 (73.33)    2.34          0.29          1.32        4.16    0.004[a](#j_bjmg-2016-0007_fn_020){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_028]\]   China             271        180        75         196 (72.32)   32    148 (82.22)   0.57          0.24          0.35        0.90    0.016[a](#j_bjmg-2016-0007_fn_020){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_029]\]   India             151        200        105        46 (30.46)    163   37 (18.50)    1.93          0.25          1.17        3.17    0.010[a](#j_bjmg-2016-0007_fn_020){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_030]\]   India             522        315        378        144 (27.59)   251   64 (20.32)    1.49          0.17          1.07        2.09    0.019[a](#j_bjmg-2016-0007_fn_020){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_031]\]   India             12         20         4          8 (66.67)     18    2 (10.00)     18.00         0.96          2.72        19.23   0.003[a](#j_bjmg-2016-0007_fn_020){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_032]\]   India             637        364        447        190 (29.83)   275   89 (24.45)    1.31          0.15          0.98        1.76    0.068
  \[[@j_bjmg-2016-0007_ref_033]\]   India             206        230        158        48 (23.30)    188   42 (18.26)    1.36          0.24          0.85        2.16    0.195
  \[[@j_bjmg-2016-0007_ref_034]\]   India             179        200        81         98 (54.75)    70    130 (65.00)   0.65          0.21          0.43        0.99    0.042[a](#j_bjmg-2016-0007_fn_020){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_035]\]   India             100        100        86         14 (14.00)    81    19 (19.00)    0.69          0.38          0.33        1.48    0.342
  \[[@j_bjmg-2016-0007_ref_036]\]   Iran              164        328        58         106 (64.63)   144   184 (56.10)   1.43          0.20          0.97        2.11    0.070
  \[[@j_bjmg-2016-0007_ref_037]\]   Iran              118        132        51         67 (56.78)    77    55 (41.67)    1.84          0.26          1.11        3.04    0.017[a](#j_bjmg-2016-0007_fn_020){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_038]\]   Iran              242        255        109        133 (54.96)   144   111 (43.53)   1.58          0.18          1.11        2.26    0.011[a](#j_bjmg-2016-0007_fn_020){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_039]\]   Iran              266        77         153        113 (42.48)   33    44 (57.14)    0.55          0.26          0.33        0.92    0.024[a](#j_bjmg-2016-0007_fn_020){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_040]\]   Iran              300        303        161        139 (46.33)   151   152 (50.17)   0.86          0.16          0.62        1.18    0.347
  \[[@j_bjmg-2016-0007_ref_041]\]   Korea             371        396        103        268 (72.24)   145   251 (63.38)   1.50          0.16          1.11        2.04    0.009[a](#j_bjmg-2016-0007_fn_020){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_042]\]   Korea             360        325        115        245 (68.06)   118   207 (63.69)   1.21          0.16          0.88        1.67    0.229
  \[[@j_bjmg-2016-0007_ref_043]\]   Korea             85         246        30         55 (64.71)    87    159 (64.63)   1.00          0.26          0.60        1.68    0.990
  **Caucasian**                                                                                                                                                          
  \[[@j_bjmg-2016-0007_ref_044]\]   Brazil            156        233        81         75 (48.08)    167   66 (28.33)    2.34          0.22          1.53        3.58    0.000[a](#j_bjmg-2016-0007_fn_020){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_045]\]   Brazil            133        173        66         67 (50.38)    136   37 (21.39)    3.73          0.25          2.27        6.14    0.000[a](#j_bjmg-2016-0007_fn_020){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_046]\]   Slovenia          100        111        29         71 (71.00)    47    64 (57.66)    1.80          0.29          1.01        3.19    0.045[a](#j_bjmg-2016-0007_fn_020){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_047]\]   Italy             59         46         11         48 (81.36)    18    28 (60.87)    2.81          0.45          1.16        6.78    0.022[a](#j_bjmg-2016-0007_fn_020){ref-type="table-fn"}
  \[[@j_bjmg-2016-0007_ref_048]\]   Italy             93         105        37         56 (60.22)    43    62 (59.05)    1.05          0.29          0.59        1.85    0.867
  \[[@j_bjmg-2016-0007_ref_049]\]   Turkey            100        50         44         56 (56.00)    30    20 (40.00)    1.91          0.35          0.96        3.81    0.066
  \[[@j_bjmg-2016-0007_ref_050]\]   Germany           255        200        114        141 (55.29)   92    108 (54.00)   1.05          0.19          0.73        1.53    0.783
  \[[@j_bjmg-2016-0007_ref_051]\]   The Netherlands   77         113        42         35 (45.45)    50    63 (55.75)    0.66          0.30          0.37        1.18    0.164
  \[[@j_bjmg-2016-0007_ref_052]\]   Serbia            52         56         22         30 (57.69)    23    33 (58.93)    0.95          0.39          0.44        2.04    0.896
  \[[@j_bjmg-2016-0007_ref_053]\]   Poland            284        352        143        256 (64.16)   166   316 (65.56)   0.94          0.14          0.71        1.24    0.665
  \[[@j_bjmg-2016-0007_ref_054]\]   Jordan            150        150        67         83 (55.33)    74    76 (50.67)    1.21          0.23          0.77        1.90    0.418
  \[[@j_bjmg-2016-0007_ref_055]\]   Sweden            149        182        73         76 (51.01)    94    88 (48.35)    1.11          0.22          0.72        1.72    0.631
  \[[@j_bjmg-2016-0007_ref_056]\]   France            250        114        118        132 (52.80)   49    65 (57.02)    0.84          0.23          0.54        1.32    0.454
  \[[@j_bjmg-2016-0007_ref_057]\]   Russia            180        301        89         91 (50.56)    153   148 (49.17)   1.06          0.19          0.73        1.53    0.769
  \[[@j_bjmg-2016-0007_ref_058]\]   Canada            39         19         22         17 (43.59)    8     11 (57.89)    0.56          0.57          0.19        1.70    0.308

A *p* value of \<0.05 was considered to be significant.

OR: odds ratio; SE: standard error.

In addition, the *MTHFR* C677T association with male infertility was also affected by folate supplementation, usually prescribed in infertility. The status of folate and supplementation is not mentioned in the previous studies except four \[[@j_bjmg-2016-0007_ref_034],[@j_bjmg-2016-0007_ref_036],[@j_bjmg-2016-0007_ref_042],[@j_bjmg-2016-0007_ref_055]\].

Although a single study that took folate levels as a factor of infertility in Caucasian men also found no association of 677T with male infertility, we can assume, depending on the socioeconomic and health facilities that the Caucasians may have comparatively more chances of folate supplementation than Asians, thus lowering the association of 677T with infertility \[[@j_bjmg-2016-0007_ref_042],[@j_bjmg-2016-0007_ref_059],[@j_bjmg-2016-0007_ref_060]\]. The previous studies described that 35.0% of the Pakistani population is folate deficient (61) and no organized folate supplementation program is currently working for the general population.

Conclusions {#j_bjmg-2016-0007_s_006}
===========

The present study of the association between idiopathic sperm disorders and the *MTHFR* 677T polymorphism suggests that the polymorphism might be a factor of male infertility in Pakistan. The results showed a significantly *(p* \<0.05) higher T allele and gene frequencies in the infertile men as compared to the fertile men. Furthermore, the carriers of the T allele were more in all semen groups of infertile men as compared to the control group. Association of male infertility with *MTHFR* C677T polymorphisms provokes investigation of the effects of folic acid supplementation in infertile men on sperm parameters. However, the present study is about only one ethnic group in Pakistan, which was self-defined by the subjects, while, MTHFR 677T frequencies in the Pakistani populations have been reported to be greatly variable and may influence the frequencies of SNPs. Therefore, studies must be conducted to investigate the association of SNPs also at the ethnic level. Secondly, the screening of infertile men must include karyotyping that was not done in the present study. We suggest that further studies must consider folate levels and folate supplementation while selecting subjects in genetic studies. Similarly, the studies must consider other well defined factors of reproductive health, general health and lifestyle factors in exclusion criteria. Further research, analyzing multiple fertility regions/loci in idiopathic infertile men is also required through high throughput analyzers, *i.e*., microarray, *etc*.
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